Literature DB >> 8188891

Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients.

P J Altmeyer1, U Matthes, F Pawlak, K Hoffmann, P J Frosch, P Ruppert, S W Wassilew, T Horn, H W Kreysel, G Lutz.   

Abstract

BACKGROUND: Psoriasis vulgaris may benefit from treatment with fumaric acid and/or its derivatives; however, because different preparations have been used, results have been contradictory and difficult to interpret.
OBJECTIVE: The purpose of this clinical trial was to evaluate the therapeutic value of fumaric acid derivatives.
METHODS: A randomized double-blind study was carried out in patients with psoriasis, comparing a well-characterized formulation of fumaric acid derivatives with placebo.
RESULTS: The results indicated statistically significant superiority of the fumaric acid derivatives over placebo. Adverse events (flush, gastrointestinal disturbances) were initially relatively frequent, but decreased thereafter.
CONCLUSION: Fumaric acid derivatives were found to be effective and safe in the treatment of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8188891     DOI: 10.1016/s0190-9622(94)70121-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  56 in total

1.  Pharmacokinetics of oral fumarates in healthy subjects.

Authors:  Nicolle H R Litjens; Jacobus Burggraaf; Elisabeth van Strijen; Co van Gulpen; Herman Mattie; Rik C Schoemaker; Jaap T van Dissel; H Bing Thio; Peter H Nibbering
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

Review 2.  Fumaric acid esters for psoriasis: a systematic review.

Authors:  D Smith
Journal:  Ir J Med Sci       Date:  2016-06-07       Impact factor: 1.568

3.  IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.

Authors:  K Asadullah; W Sterry; K Stephanek; D Jasulaitis; M Leupold; H Audring; H D Volk; W D Döcke
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

4.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 5.  Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders.

Authors:  Vittorio Calabrese; Carolin Cornelius; Albena T Dinkova-Kostova; Edward J Calabrese; Mark P Mattson
Journal:  Antioxid Redox Signal       Date:  2010-08-28       Impact factor: 8.401

Review 6.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Ignacio Garcia-Doval; Giao Do; Camille Hua; Canelle Mazaud; Catherine Droitcourt; Carolyn Hughes; John R Ingram; Luigi Naldi; Olivier Chosidow; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2017-12-22

7.  Anti-Psoriatic Drug Monomethylfumarate Increases Nuclear Factor Erythroid 2-Related Factor 2 Levels and Induces Aquaporin-3 mRNA and Protein Expression.

Authors:  Inas Helwa; Vivek Choudhary; Xunsheng Chen; Ismail Kaddour-Djebbar; Wendy B Bollag
Journal:  J Pharmacol Exp Ther       Date:  2017-05-17       Impact factor: 4.030

8.  Influence of dimethylfumarate on experimental HSV-1 necrotizing keratitis.

Authors:  A Heiligenhaus; H Li; S Wasmuth; D Bauer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-07-06       Impact factor: 3.117

9.  Fumaric Acid and its esters: an emerging treatment for multiple sclerosis.

Authors:  D Moharregh-Khiabani; R A Linker; R Gold; M Stangel
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation.

Authors:  Henrik Wilms; Jobst Sievers; Uta Rickert; Martin Rostami-Yazdi; Ulrich Mrowietz; Ralph Lucius
Journal:  J Neuroinflammation       Date:  2010-05-19       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.